

AUG. 18. 2006 4:00PM

CHOATE HALL & STEWART 6172484000

NO. 900 P. 1

CHOATE

CHOATE HALL & STEWART LLP

RECEIVED
CENTRAL FAX CENTER

AUG 18 2006

Fax

Recipient	Company	Fax	Phone
Examiner Fubara, Group 1618	USPTO	571-273-8300	571-272-0594

From	C. Hunter Baker, M.D., Ph.D.	Number of Pages	5
Date	August 18, 2006	Client Number	0492611-0417
Phone	(617) 248-5215	Operator	Time Sent

Comments

ATTORNEY'S DOCKET NUMBER: 0492611-0417 (MIT 8966)
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Kohane <i>et al.</i>	Examiner:	Fubara, Blessing M.
Serial No.:	09/981,020	Art Unit:	1618
Filed:	October 16, 2001		
For:	LIPID-PROTEIN-SUGAR PARTICLES FOR DRUG DELIVERY		

Dear Examiner Fubara:

Attached is a set of amended claims to facilitate our discussion of this application next Tuesday (August 22nd) at 10 am. Please do *not* enter these amendments into the case at this time. We look forward to speaking with you next week.

Sincerely,

C. Hunter Baker, M.D., Ph.D. and

Nicole Clouse, Ph.D.

This Message is transmitted to you by the law firm of Choate, Hall & Stewart LLP. The substance of this message, along with any attachments, may be confidential and legally privileged. If you are not the designated recipient of this message, please destroy it and notify the sender of the error by return e-mail or by calling 1-800-520-2427.

Under regulations of the Treasury Department, we are required to include the following statement in this message: Any advice contained herein (or in any attachment hereto) regarding federal tax matters was not intended or written by the sender to be used, and it cannot be used by any taxpayer, for the purpose of avoiding penalties that may be imposed on the taxpayer.

For more information about Choate, Hall & Stewart LLP, please visit us at www.choate.com

Two International Place | Boston MA 02110 | t 617-248-5000 | f 617-248-4000 | choate.com

4114944v1

DRAFT*Please do NOT enter claims into case.***RECEIVED
CENTRAL FAX CENTER****ATTORNEY'S DOCKET NUMBER: 0492611-0417 (MIT 8966)****AUG 18 2006****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant:	Kohane <i>et al.</i>	Examiner:	Fubara, Blessing M.
Serial No.:	09/981,020	Art Unit:	1618
Filed:	October 16, 2001		
For:	LIPID-PROTEIN-SUGAR PARTICLES FOR DRUG DELIVERY		

Listing of Drafted Claims

86. A pharmaceutical composition comprising solid microparticles, wherein the microparticles are not liposomes, comprising:

- (a) a matrix comprising:
 - (i) dipalmitoyl phosphatidylcholine (DPPC);
 - (ii) a sugar selected from the group consisting of galactose, lactose, glucose, maltose, starches, cellulose and its derivatives, methyl cellulose, carboxymethyl cellulose, fructose, dextran and its derivatives, raffinose, mannitol, xylose, dextrans, glycosaminoglycans, sialic acid, chitosan, hyaluronic acid, and chondroitin sulfate; and
 - (iii) a protein; and
- (b) an agent, wherein the agent is encapsulated in the matrix.

87. A pharmaceutical composition comprising solid microparticles, wherein the microparticles are not liposomes, comprising:

- (a) a matrix comprising:
 - (i) a lipid selected from the groups consisting of phosphoglycerides; phosphatidylcholines; dipalmitoyl phosphatidylcholine (DPPC); dioleoylphosphatidyl ethanolamine (DOPE); dioleoyloxypropyltriethylammonium (DOTMA); dioleoylphosphatidylcholine; cholesterol; cholesterol ester;

Page 1 of 4

U.S.S.N. 09/981,020
4072821v2Attorney's Docket Number: 0492611-0417
MIT's Reference Number: 8966

DRAFT***Please do NOT enter claims into case.***

diacylglycerol; diacylglycerolsuccinate; diphosphatidyl glycerol (DPPG); hexanodecanol; fatty alcohols; polyethylene glycol (PEG); polyoxyethylene-9-lauryl ether; a surface active fatty acid; palmitic acid; oleic acid; fatty acids; fatty acid amides; sorbitan trioleate (Span 85) glycocholate; surfactin; a poloxomer; a sorbitan fatty acid ester; sorbitan trioleate; lecithin; lysolecithin; phosphatidylserine; phosphatidylinositol; sphingomyelin; phosphatidylethanolamine (cephalin); cardiolipin; phosphatidic acid; cerebrosides; dicetylphosphate; dipalmitoylphosphatidylglycerol; stearylamine; dodecylamine; hexadecyl-amine; acetyl palmitate; glycerol ricinoleate; hexadecyl stearate; isopropyl myristate; tyloxapol; poly(ethylene glycol)5000-phosphatidylethanolamine; and phospholipids;

- (ii) lactose; and
- (iii) a protein; and
- (b) an agent, wherein the agent is encapsulated in the matrix.

88. A pharmaceutical composition comprising solid microparticles, wherein the microparticles are not liposomes, comprising:

- (a) a matrix comprising:
 - (i) a lipid selected from the groups consisting of phosphoglycerides; phosphatidylcholines; dipalmitoyl phosphatidylcholine (DPPC); dioleoylphosphatidyl ethanolamine (DOPE); dioleoyloxypropyltriethylammonium (DOTMA); dioleoylphosphatidylcholine; cholesterol; cholesterol ester; diacylglycerol; diacylglycerolsuccinate; diphosphatidyl glycerol (DPPG); hexanodecanol; fatty alcohols; polyethylene glycol (PEG); polyoxyethylene-9-lauryl ether; a surface active fatty acid; palmitic acid; oleic acid; fatty acids; fatty acid amides; sorbitan trioleate (Span 85) glycocholate; surfactin; a poloxomer; a sorbitan fatty acid ester; sorbitan trioleate; lecithin; lysolecithin;

Page 2 of 4

U.S.S.N. 09/981,020
4072821v2Attorney's Docket Number: 0492611-0417
MIT's Reference Number: 8966

DRAFT

Please do NOT enter claims into case.

phosphatidylserine; phosphatidylinositol; sphingomyelin;
phosphatidylethanolamine (cephalin); cardiolipin; phosphatidic
acid; cerebrosides; dicetylphosphate;
dipalmitoylphosphatidylglycerol; stearylamine; dodecylamine;
hexadecyl-amine; acetyl palmitate; glycerol ricinoleate; hexadecyl
stearate; isopropyl myristate; tyloxapol; poly(ethylene glycol)5000-
phosphatidylethanolamine; and phospholipids;

(ii) a sugar selected from the group consisting of galactose, lactose,
glucose, maltose, starches, cellulose and its derivatives, methyl
cellulose, carboxymethyl cellulose, fructose, dextran and its
derivatives, raffinose, mannitol, xylose, dextrans,
glycosaminoglycans, sialic acid, chitosan, hyaluronic acid, and
chondroitin sulfate; and

(iii) a protein; and

(b) an agent, wherein the agent is encapsulated in the matrix.

89. The pharmaceutical composition of claim 88, wherein the protein is albumin.

90. A pharmaceutical composition comprising solid microparticles, wherein the
microparticles are not liposomes, comprising:

(a) a matrix comprising:

(i) dipalmitoyl phosphatidylcholine (DPPC);

(ii) lactose; and

(iii) albumin; and

(b) an agent, wherein the agent is encapsulated in the matrix.

91. The pharmaceutical compositions of any one of claims 86-90, wherein the ratio of lipid to
protein to sugar is approximately 3:1:1.

92. The pharmaceutical compositions of any one of claims 86-90, wherein the ratio of lipid to
protein to sugar to agent is approximately 54:18:18:10.

DRAFT***Please do NOT enter claims into case.***

93. The pharmaceutical compositions of any one of claims 86-90, wherein the lipid comprises 20-60% of the matrix by weight; wherein the protein comprises 10-30% of the matrix by weight; and wherein the sugar comprises 10-30% of the matrix by weight.
94. The pharmaceutical compositions of any one of claims 86-90, wherein the agent is a small molecule.
95. The pharmaceutical compositions of any one of claims 86-90, wherein the agent is a protein.
96. The pharmaceutical compositions of any one of claims 86-90, wherein the agent is a polynucleotide.